APA (7th ed.) Citation

Pérez-Calvo, F., Jover-Diaz, F., Delgado-Sánchez, E., Peris-García, J., Bernabéu-Martínez, M. Á., & Carradori, S. (2025). BIKSWITCH Study: Effectiveness and Safety of Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) From Therapies Not Based on Integrase Inhibitors in Virologically Suppressed HIV‐Infected Patients. AIDS Research & Treatment, 2025, 1. https://doi.org/10.1155/arat/8818830

Chicago Style (17th ed.) Citation

Pérez-Calvo, Fernando, Francisco Jover-Diaz, Elisabet Delgado-Sánchez, Jorge Peris-García, María Ángeles Bernabéu-Martínez, and Simone Carradori. "BIKSWITCH Study: Effectiveness and Safety of Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) From Therapies Not Based on Integrase Inhibitors in Virologically Suppressed HIV‐Infected Patients." AIDS Research & Treatment 2025 (2025): 1. https://doi.org/10.1155/arat/8818830.

MLA (9th ed.) Citation

Pérez-Calvo, Fernando, et al. "BIKSWITCH Study: Effectiveness and Safety of Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) From Therapies Not Based on Integrase Inhibitors in Virologically Suppressed HIV‐Infected Patients." AIDS Research & Treatment, vol. 2025, 2025, p. 1, https://doi.org/10.1155/arat/8818830.